RAPIGLINIDE VOG 1 LD
Item requires a valid prescription
Manufactured By Steris Healthcare Pvt Ltd
Composition Voglibose 0.2 mg And Repaglinide 1 mg Tablets IP
Rs 150.00
MRP Rs 215.00
(30% OFF)
Includes all taxes
Package SIZE
( For 15 Tablets )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
RAPIGLINIDE VOG 1 LD is a two-in-one oral antidiabetic tablet from Steris Pharma, containing Repaglinide 1 mg and Voglibose 0.2 mg. It is meant for adults with Type 2 Diabetes Mellitus and should be used only when prescribed by a qualified healthcare professional.
Type 2 Diabetes is a long-term metabolic condition in which blood glucose stays high because the body resists insulin and does not produce enough of it. Keeping glucose within a healthy range lowers the risk of long-term diabetes complications.
The two ingredients act in different ways. Repaglinide prompts the pancreas to release insulin around mealtimes, while Voglibose slows the digestion and absorption of carbohydrates in the gut, which blunts the sharp rise in glucose after eating. Together they offer a complementary approach under medical supervision.
Composition
Each tablet contains:
- Repaglinide: 1 mg
- Voglibose: 0.2 mg
Dosage form: Tablets IP
Manufactured/Marketed by: Steris Pharma
Key Benefits
1. Helps Control Post-Meal Glucose
Voglibose is an alpha-glucosidase inhibitor. It delays the breakdown of complex carbohydrates into absorbable sugars, so glucose enters the blood more gradually after meals.
2. Boosts Insulin Release
Repaglinide is a meglitinide-class medicine. It stimulates the pancreatic beta cells to secrete insulin, especially in response to food.
3. Two Mechanisms in One Tablet
Repaglinide supports insulin release while Voglibose slows carbohydrate digestion and glucose absorption, so post-meal glucose is addressed from two directions.
4. Supports Overall Glucose Management
When taken as prescribed, this tablet can help improve glucose control in suitable adults with Type 2 Diabetes. It works best alongside a proper diet, regular physical activity and routine glucose monitoring.
How Does It Work?
Repaglinide 1 mg: A short-acting insulin secretagogue. It acts on ATP-sensitive potassium channels in pancreatic beta cells, triggering insulin release in response to meals and limiting the rise in blood glucose after eating.
Voglibose 0.2 mg: An alpha-glucosidase inhibitor. It blocks the enzymes that break carbohydrates down into simple sugars in the small intestine, so digestion and glucose absorption are delayed and post-meal peaks are reduced.
Combined action: The tablet addresses two key processes behind post-meal glucose regulation. A doctor may prescribe it when both mechanisms suit a patient’s treatment plan.
Uses
RAPIGLINIDE VOG 1 LD is prescribed for:
- Managing Type 2 Diabetes Mellitus in suitable adult patients
- Improving glucose control after meals
- Supporting overall glycemic management within an individualized treatment plan
- Patients for whom their doctor considers a short-acting insulin secretagogue plus an alpha-glucosidase inhibitor appropriate
It is not meant for Type 1 Diabetes Mellitus or diabetic ketoacidosis.
Important Precautions and Safety Information
Use this medicine carefully and strictly as advised by your doctor.
- Low blood glucose (hypoglycemia): Repaglinide can cause blood glucose to fall too low. Signs include sweating, shakiness, dizziness, hunger, headache, confusion and palpitations. Patients should know how to recognize and manage these symptoms.
- Meal timing: Repaglinide is usually taken shortly before a meal, as your doctor directs. If a meal is skipped, the dose should be skipped too, as per the prescribed instructions. Never change the schedule on your own.
- Digestive effects: Voglibose may cause abdominal discomfort, gas and diarrhea.
- Existing conditions: Tell your doctor before starting if you have liver or kidney problems or take other antidiabetic medicines.
- Pregnancy and breastfeeding: If you are pregnant, planning pregnancy or breastfeeding, ask your healthcare professional about suitable diabetes treatment.
- Monitoring: Regular blood glucose checks and periodic HbA1c tests help assess how well the treatment is working.
- Treating a low: Because Voglibose slows the breakdown of sucrose, patients who develop hypoglycemia should take glucose (dextrose) rather than ordinary table sugar for quick correction.
Why Choose RAPIGLINIDE VOG 1 LD?
This tablet brings two established antidiabetic ingredients together in one convenient dose.
- Contains Repaglinide 1 mg and Voglibose 0.2 mg
- Two complementary mechanisms of glucose regulation
- Supports management of post-meal glucose
- Helps stimulate insulin release at mealtimes
- Helps delay carbohydrate digestion in the intestine
- For adults with Type 2 Diabetes when medically indicated
- Part of the Steris Pharma pharmaceutical portfolio
Steris Pharma develops pharmaceutical formulations for a range of therapeutic needs and aims to support healthcare professionals in patient care.
Conclusion
RAPIGLINIDE VOG 1 LD from Steris Pharma is a combination antidiabetic tablet (IP) with Repaglinide 1 mg and Voglibose 0.2 mg. By stimulating insulin secretion and slowing carbohydrate digestion, it targets rises in blood glucose after meals.
For suitable adults with Type 2 Diabetes, it can be one option within an individualized management plan under medical supervision.
Frequently Asked Questions (FAQs)
Q1. What is RAPIGLINIDE VOG 1 LD?
It is a combination antidiabetic tablet with Repaglinide 1 mg and Voglibose 0.2 mg, prescribed to manage Type 2 Diabetes Mellitus in suitable adults.
Q2. What active ingredients does it contain?
Two: Repaglinide 1 mg and Voglibose 0.2 mg.
Q3. How does Repaglinide work?
It signals the pancreas to release insulin, which helps regulate blood glucose, mainly after meals.
Q4. What does Voglibose do?
It slows carbohydrate digestion and glucose absorption in the gut, which reduces post-meal glucose rises.
Q5. Can it be used for Type 1 Diabetes?
No. It is intended for suitable adults with Type 2 Diabetes Mellitus and is not indicated for Type 1.
Q6. What side effects can occur?
Possible effects include hypoglycemia, abdominal discomfort, gas and diarrhea. Consult a healthcare professional if symptoms persist or become severe.
Q7. Should it be taken before or after meals?
Repaglinide is usually taken shortly before meals. Follow your doctor’s exact instructions, especially when a meal is skipped.